| Identification | Back Directory | [Name]
sodium(R)-2-(5-(2-(3-ethylureido)-6-fluoro-7-(tetrahydrofuran-2-yl)-1H-benzo[d]imidazol-5-yl)pyrimidin-2-yl)propan-2-ylphosphate | [CAS]
1384984-20-6 | [Synonyms]
EOS-60705
SPR720 disodium
pVXc-486 disodium
Fobrepodacin disodium
sodium(R)-2-(5-(2-(3-ethylureido)-6-fluoro-7-(tetrahydrofuran-2-yl)-1H-benzo[d]imidazol-5-yl)pyrimidin-2-yl)propan-2-ylphosphate | [Molecular Formula]
C21H27FN6NaO6P | [MOL File]
1384984-20-6.mol | [Molecular Weight]
532.44 |
| Hazard Information | Back Directory | [Uses]
Fobrepodacin (SPR720) disodium is an orally active and potent phosphate proagent of SPR719 (VXc-486; HY-12930). Fobrepodacin disodium has potent bactericidal activities in vivo[1]. | [in vivo]
Fobrepodacin disodium (oral gavage; 10, 30, 100 mg/kg; once per day; 5 times per week for 4 weeks) reduces the mycobacterial burden in a model of chronic tuberculosis infection in mice[1].
Fobrepodacin disodium (oral; 100 mg/kg; once per day; 5 days per week, for 8 weeks) improves the bactericidal activities of antimycobacterial drugs[1].
| Animal Model: | Six-week old female BALB/c and C57BL/6 mice uninfected or M. tuberculosis-infected (Erdman)[1] | | Dosage: | 10, 30, 100 mg/kg | | Administration: | Oral gavage; once per day; 5 times per week for 4 weeks | | Result: | Reduced the mycobacterial burden in a model of chronic tuberculosis infection in mice.
|
| [References]
[1] Locher CP, et al. A novel inhibitor of gyrase B is a potent drug candidate for treatment of tuberculosis and nontuberculosis mycobacterial infections.Antimicrob Agents Chemother. 2015 Mar;59(3):1455-65. DOI:10.1128/AAC.04347-14 |
|
|